多発性硬化症治療薬の市場規模、シェア、成長分析：タイプ別、投与経路別、流通チャネル別、地域別 - 産業予測 2025～2032年

多発性硬化症治療薬市場規模は2023年に284億米ドルと評価され、2024年の296億2,000万米ドルから2032年には414億8,000万米ドルに成長し、予測期間中（2025-2032年）のCAGRは4.3％で成長する見通しです。

多発性硬化症（MS）市場は、疾病負担の増大と効果的な治療薬に対する需要の高まりにより、大きな成長が見込まれています。MSの有病率が高まるにつれ、大手製薬企業は革新的な治療法の開発に向けた研究開発努力を強化しており、有利なビジネスチャンスを生み出しています。特にAdamas Pharmaceuticals Inc.は、MSの治験薬ADS-5102の第3相試験で有望な結果を得たと発表しました。さらに、製品上市や治療へのアクセス向上を目指した政府の取り組みが、市場拡大をさらに後押しすると思われます。在宅用経鼻抗CD3モノクローナル抗体などの新規治療薬の導入は、MS治療の選択肢を前進させるという業界のコミットメントを例証するものです。全体として、米国のMS治療薬市場は、今後の予測期間においても持続的なCAGRを維持すると予想されます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

多発性硬化症治療薬市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 免疫調節薬
• インターフェロン
• 免疫抑制剤
• その他のタイプ

多発性硬化症治療薬市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 非経口
• その他

多発性硬化症治療薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• オンライン薬局
• 小売薬局
• その他の流通チャネル

多発性硬化症治療薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Biogen Inc.（United States）
• Roche Holdings AG（Switzerland）
• Novartis AG（Switzerland）
• Sanofi S.A.（France）
• Merck & Co., Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Bayer AG（Germany）
• Pfizer Inc.（United States）
• GlaxoSmithKline plc（United Kingdom）
• AbbVie Inc.（United States）
• Johnson & Johnson Services, Inc.（United States）
• Celgene Corporation（United States）
• Bristol-Myers Squibb Company（United States）
• Mitsubishi Tanabe Pharma Corporation（Japan）
• Biogen Idec International GmbH（Switzerland）
• Genzyme Corporation（United States）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Merck KGaA（Germany）
• Mylan N.V.（United States）

結論と提言

Multiple Sclerosis Drugs Market size was valued at USD 28.4 billion in 2023 and is poised to grow from USD 29.62 billion in 2024 to USD 41.48 billion by 2032, growing at a CAGR of 4.3% during the forecast period (2025-2032).

The multiple sclerosis (MS) market is poised for significant growth due to an increasing disease burden and rising demand for effective therapeutics. As the prevalence of MS grows, major pharmaceutical companies are intensifying their R&D efforts to develop innovative treatments, creating lucrative opportunities. Notably, Adamas Pharmaceuticals Inc. has announced promising results from its phase 3 trial of ADS-5102, an investigational agent for MS. Additionally, product launches and government initiatives aimed at improving treatment accessibility will further support market expansion. The introduction of novel therapies, such as an intranasal anti-CD3 monoclonal antibody for at-home use, exemplifies the industry's commitment to advancing MS treatment options. Overall, the US MS drugs market is expected to maintain a sustainable CAGR in the coming forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Multiple Sclerosis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Multiple Sclerosis Drugs Market Segments Analysis

Global Multiple Sclerosis Drugs Market is segmented by Type, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Immunomodulators, Interferons, Immunosuppressants and Other types. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Other Distribution Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Multiple Sclerosis Drugs Market

The escalating prevalence of multiple sclerosis (MS) worldwide significantly propels the growth of the multiple sclerosis drugs market. According to the National Multiple Sclerosis Society, approximately 2.8 million individuals globally are affected by MS, a figure that is on the rise, particularly in more developed regions. This increasing patient population underscores the urgent need for advanced therapies aimed at managing disease progression effectively. As the demand for innovative treatment options grows, pharmaceutical companies are driven to invest in research and development to cater to the evolving needs of patients suffering from MS, further stimulating the market's expansion.

Restraints in the Multiple Sclerosis Drugs Market

The high cost associated with treatments for multiple sclerosis presents a significant obstacle to market growth. Many disease-modifying therapies, particularly those related to chemotherapy and oral medications, are priced at premium levels, rendering them inaccessible for patients lacking comprehensive insurance coverage. This financial strain is especially severe in both high-income and low-income countries where health systems may not possess the necessary resources to provide or support these expensive treatments effectively. As a result, the affordability issue creates a substantial barrier to accessing vital therapies, ultimately hindering market potential and patient care in the multiple sclerosis treatment landscape.

Market Trends of the Multiple Sclerosis Drugs Market

In the Multiple Sclerosis (MS) drugs market, a significant trend is the acceleration towards personalized medicine and biomarker-based therapies. Advances in genetics and molecular biology are facilitating the identification of specific biomarkers that predict disease progression and patient response to treatment. This shift is fostering the creation of tailored therapeutic solutions designed to optimize efficacy and minimize side effects for individuals with MS. As healthcare providers increasingly emphasize personalized treatment approaches, pharmaceutical companies are prioritizing research and development of targeted therapies, thereby reshaping the landscape of MS treatment and fostering improved outcomes and quality of life for patients.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Multiple Sclerosis Drugs Market Size by Type & CAGR (2025-2032)

• Market Overview
• Immunomodulators
• Interferons
• Immunosuppressants
• Other types

Global Multiple Sclerosis Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Others

Global Multiple Sclerosis Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Distribution Channels

Global Multiple Sclerosis Drugs Market Size & CAGR (2025-2032)

• North America (Type, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holdings AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Idec International GmbH (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genzyme Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations